pegcetacoplan (Empaveli, Syfovre)
Jump to navigation
Jump to search
Indications
- treatment of adults with paroxysmal nocturnal hemoglobinuria
- geographic atrophy secondary to age-related macular degeneration (Syfovre)[2]
Contraindications
- Syfovre: ocular or periocular infections or active intraocular inflammation[2]
Dosage
- 1,080 mg twice weekly
- may be given in addition to eculizumab
- Syfovre injection administered every 25-60 days for geographic atrophy[2]
Adverse effects
- serious infections caused by encapsulated bacteria
- life-threatening meningococcal infections
- viral infections
- respiratory tract infection
- diarrhea
- abdominal pain
Mechanism of action
- binds to complement-C3
Notes
- available only through a restricted program under a risk evaluation & mitigation strategy (REMS)
- Syfovre cost: $2190 per vial[2]
More general terms
References
- ↑ FDA Drug Approval. May 18, 2021 FDA approves new treatment for adults with serious rare blood disease https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-new-treatment-adults-serious-rare-blood-disease
- ↑ 2.0 2.1 2.2 2.3 2.4 Marcus A FDA OKs First Drug for Geographic Atrophy, a Major Cause of Adult Blindness. Medscape. February 17, 2023 https://www.medscape.com/viewarticle/988460